Recursion Pharmaceuticals (NASDAQ: RXRX)
Recursion Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Recursion Pharmaceuticals Company Info
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
News & Analysis
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
This company stands to benefit from a shifting pharmaceutical industry landscape.
Prediction: These 2 Stocks Could Soar in 2025
The key word here is "could."
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
Wood has a stake in this stock, but it's hardly an "all-in" bet.
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.